Don’t Settle for Metal

About Us

Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation: “Bio-Integrative” implants that have both the desired strength AND bio-friendliness. Implants that have the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables” and other “bio-composites”), have remained elusive to the industry — until now.

Look at the Leaders of OSSIO

Brian Verrier

Chief Executive Officer

Orahn Preiss-Bloom

Founder & Chief Innovation Officer

Brennan Marilla

Chief Commercial & Operating Officer

Featured Services and Innovations

OSSIOfiber

OSSIOfiber^® is the first-of-its kind implant material to securely fixate and fully integrate into the native anatomy with nothing left behind.

Unlike other implants, OSSIOfiber^® contains the same natural minerals found in bones themselves, but it’s stronger—it eventually becomes part of the bone, encouraging a return to full strength naturally without the risks and costs associated with permanent hardware.¹

Company Spotlight Video

News and Stories

OSSIO’s Groundbreaking Option for Fixing Bone Fractures In Children Receives FDA Clearance

WOBURN, Mass. December 6, 2023–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation technology company, on Friday received “breaking” news from the U.S. Food and Drug Administration (FDA):

The FDA has cleared the company’s OSSIOfiber^® bio-integrative fixation technology for use in orthopedic surgery for children and adolescents needing bone fractures fixed, osteotomies, or fusions. As a result, OSSIOfiber Compression Screws and Trimmable Fixation Nails may now be used in children from age two to 21 years in standard clinical practice.

OSSIO Launches World’s First and Only Non-Permanent Compression Staple

WOBURN, Mass. February 7, 2023–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation technology company, today announced the introduction of the new OSSIOfiber® Compression Staple, the next step towards becoming the gold standard in orthopedic fixation. OSSIO’s fifth product family, OSSIOfiber® Compression Staples, allow surgeons to evolve to stronger, bio-integrative compression.

OSSIO Closes Series C Financing of $38.5 Million

WOBURN, Mass. October 17, 2022–(BUSINESS WIRE)–OSSIO, Ltd., a fast-growing orthopedic fixation technology company, announced today that it has closed $38.5 million in Series C financing. Along with the participation of current shareholders, the round was led by MVM Partners, a Boston- and London-based growth equity firm investing in innovative, commercial stage healthcare companies that address high unmet medical needs.

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!